A researcher in a lab looking at a tablet.

Tag: patient education

  • blue circle with "ALKtALK by ALK+ Positive."

    Dr. Shirish Gadgeel

    Join us for ALKtALK with Shirish Gadgeel, MD, and gain a deeper understanding of the essential role chemotherapy plays in ALK-positive cancer care.

    Read More

  • The two most surprising risk factors for lung cancer

    Worldwide about 2,100,000 people are diagnosed with lung cancer every year. Approximately 85% of them have used tobacco products. Most are older and in poor health. It’s an insidious disease […]

    Read More

  • ALK patients with hight PD-L1 expression and immunotherapy

    Many of our members are wondering if immunotherapy with current checkpoint inhibitors may be a good idea for them if they have been diagnosed with a high PD-L1 expression. Spoiler […]

    Read More

  • ,

    Side effects compliation & comparison

    IMPORTANT: This table is a list of various side effects members have shared.  Please remember, this is NOT a medical document.  Please use it as a guide and a starting point.  […]

    Read More

  • Brain Metastasis Radiation Options

    Radiation Options to Treat Brain Metastasis: Quick Review of WBR, SRS, and SFRT Nieder et. al. wrote an easy to understand paper on the management of patients with brain metastases […]

    Read More

  • Juggling a young family while dealing with a cancer diagnosis

    When someone receives a cancer diagnosis, the entire family is affected.  In this quick review, we highlight several aspects of juggling a family while dealing with a cancer diagnosis.   […]

    Read More

  • Announcing $5,000 Scholarships for Children of Parents with Rare Lung Cancer

    $5000 SCHOLARSHIPS FOR CHILDREN OF PARENTS WITH RARE LUNG CANCER College scholarship enabled by the family of Regina Dieker Kay & ALK Positive   Washington DC, March 15th, 2020 – […]

    Read More

  • Case Study: successful re-use of Brigatinib after Lorlatinib

    Case study: Successful re-use of Brigatinib after Lorlatinib The patient in this case study was diagnosed with ALK-positive lung cancer in 2005 and had disease progression on several occasions.  Chemotherapy […]

    Read More

  • ,

    Biomarker Testing, explained

    Ever wondered what biomarker testing really refers to and what it means for your treatment options? Read on for a simplified explanation of how biomarkers can drive cancer, how testing […]

    Read More

  • What exactly is ALK-positive lung cancer?

    Find out more about the history of ALK fusion with an emphasis on early discovery, diagnostic methods, and the development of the first targeted ALK inhibitors. ALK Lung Cancer 101 […]

    Read More

  • MET and TP 53: How they relate to ALK lung cancer

    MET Amplification MET is a receptor tyrosine kinase that participates in the hepatocyte growth factor (HGF)-mediated signaling pathway.  This protein is anchored to the cell wall to pass information from […]

    Read More

  • Free Second Opinion Program gives patients worldwide expert access

    ALK POSITIVE SECOND OPINION PROGRAM Designed to Improve Patient Outcomes and Reduce Anxiety This unique program was conceived by our generous ALK Positive member, Jim Peard. Jim was deeply concerned […]

    Read More